Although icodextrin has been shown to augment peritoneal ultrafiltration in peritoneal dialysis (PD) patients, its impact upon other clinical end points, such as technique survival, remains uncertain. This systematic review evaluated the effect of icodextrin use on patient level clinical outcomes.Methods
The Cochrane CENTRAL Registry, MEDLINE, Embase and reference lists were searched (last search 13 September 2012) for randomized controlled trials of icodextrin versus glucose in the long dwell exchange. Summary estimates of effect were obtained using a random effects model.Results
Eleven eligible trials (1222 patients) were identified. There was a significant reduction in episodes of uncontrolled fluid overload [two trials; 100 patients; relative risk (RR) 0.30, 95% confidence interval (CI) 0.15–0.59] and improvement in peritoneal ultrafiltration [four trials; 102 patients; mean difference (MD) 448.54 mL/day, 95% CI 289.28–607.80] without compromising residual renal function [four trials; 114 patients; standardized MD (SMD) 0.12, 95% CI −0.26 to 0.49] or urine output (three trials; 69 patients; MD −88.88, 95% CI −356.88 to 179.12) with icodextrin use for up to 2 years. There was no significant effect on peritonitis incidence (five trials; 607 patients; RR 0.97, 95% CI 0.76–1.23), peritoneal creatinine clearance (three trials; 237 patients; SMD 0.36, 95% CI −0.24 to 0.96), technique failure (three trials; 290 patients; RR 0.58, 95% CI 0.28–1.20), patient survival (six trials; 816 patients; RR 0.82, 95% CI 0.32–2.13) or adverse events.Conclusions
Icodextrin prescription improved peritoneal ultrafiltration, mitigated uncontrolled fluid overload and was not associated with increased risk of adverse events. No effects of icodextrin on technique or patient survival were observed, although trial sample sizes and follow-up durations were limited.